Patents Examined by Gollamudi S. Kishore
  • Patent number: 11684578
    Abstract: A liposome for use in delivering a therapeutically active agent to a subject in need thereof is disclosed herein. The liposome comprises: a) at least one bilayer-forming lipid; b) a polymeric compound having the general formula I: wherein m, n, L, X, Y, and Z are as defined herein; and c) a therapeutically active agent, incorporated in the liposome and/or on a surface of the liposome.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: June 27, 2023
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Weifeng Lin
  • Patent number: 11684579
    Abstract: A multivesicular liposome composition includes a plurality of multivesicular liposomes. Each multivesicular liposome includes a carrier liposome particle including carrier phospholipid bilayer and having an average diameter less than 1 micron; and at least one sub-chamber liposome nanoparticle including a sub-chamber liposome nanoparticle bilayer and having an average diameter less than about 50 nm. The carrier liposome particle encapsulates the at least one sub-chamber liposome nanoparticle. Characteristically, tail groups of the carrier liposome phospholipids are larger than tail groups phospholipids of the at least one sub-chamber liposome nanoparticle.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: June 27, 2023
    Inventors: Andrew Brovko Gray, Donald Dewane Johnson, Alan Michael Johnson
  • Patent number: 11680107
    Abstract: The present disclosure relates to a biodegradable and thermosensitive hydrogel composition comprising a diblock PLGA-PEG copolymer and a triblock PLGA-PEG-PLGA copolymer. A method for treating or alleviating one or more symptoms of a disease and a method for delivering an active agent are also provided.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: June 20, 2023
    Assignee: Taipei Medical University
    Inventors: Shyr-Yi Lin, Ming-Thau Sheu, Kuo-Hsiang Chuang, Yi-Jou Chen, Pu-Sheng Wei
  • Patent number: 11672784
    Abstract: According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and/or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and/or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and/or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and/or treating anterior segment ocular diseases based on the nanoliposomes.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: June 13, 2023
    Inventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Yin Chiang Freddy Boey, Jodhbir Singh Mehta, Tina Tzee Ling Howden, Xu Wen Ng, Anthony Herr Cheun Ng
  • Patent number: 11633357
    Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 25, 2023
    Assignee: ZULI HOLDINGS, LTD.
    Inventors: Yoram Richter, Yehuda Zelig, Omar Elmalak, Dror Eyal
  • Patent number: 11612769
    Abstract: Oral health care formulation and method of preparation for the same are disclosed herein. The disclosed oral care composition includes a combination of various herbs and minerals, and may be used to maintain good oral hygiene. Further, a method of oral health care is also disclosed in the various embodiments herein.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: March 28, 2023
    Inventor: M Vijayabhanu Shetty
  • Patent number: 11590079
    Abstract: The present disclosure relates to compositions comprising phospho-lipids, lipid vesicles, and/or liposomes, and methods of use thereof. In one aspect, the present disclosure relates to methods and compositions for delivery of, biologically active lipids to reduce microvascular dysfunction and infarct size during revascularization of the blocked artery in a mammalian subject.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 28, 2023
    Assignee: EndoProtech, Inc.
    Inventors: Claudio Maldonado, Phillip Bauer
  • Patent number: 11583508
    Abstract: Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 21, 2023
    Inventors: Chunlei Li, Yueying Peng, Kun Lou, Yajuan Wang, Yumei Wang, Shan Chen, Zhibin Meng, Jianfei Xue, Jing Yuan, Hongmei Luo, Xuekun Yao, Shixia Wang
  • Patent number: 11576872
    Abstract: In some aspects, fusosome compositions and methods are described herein that comprise membrane enclosed preparations, comprising a fusogen. In some embodiments, the fusosome can the target cell, thereby delivering complex biologic agents to the target cell cytoplasm.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 14, 2023
    Inventors: Geoffrey A. von Maltzahn, John Miles Milwid, Michael Travis Mee, Jacob Rosenblum Rubens, Nathan Wilson Stebbins, Molly Krisann Gibson, Neal Francis Gordon, Bo Zhang, Kyle Marvin Trudeau, Brigham Jay Hartley, Tamar Rose Putiri, Kiana Mahdaviani, Matthew Milnes Dobbin
  • Patent number: 11559486
    Abstract: Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 24, 2023
    Assignee: Acrotech Biopharma, LLC
    Inventors: William T. Monte, Robert Malcolm Abra, Bing Luo, Yuanpeng Zhang
  • Patent number: 11554128
    Abstract: The present invention relates to mineral micro-particles comprising phytate (inositol hexaphosphate, IP6). More particularly, the invention provides salts of phytic acid with multivalent metal ions such as Ca2+ and Mg2+ for use in biomolecules delivery or adsorption systems, methods for their production and uses thereof, such as for use as a vaccine adjuvant.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: January 17, 2023
    Assignee: Croda International Plc
    Inventors: Laurent Duroux, Erik Lindblad
  • Patent number: 11541008
    Abstract: The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: January 3, 2023
    Inventors: Jacob Klein, Ronit Goldberg, Yechezkel Barenholtz, Avi Schroeder
  • Patent number: 11534399
    Abstract: Provided is a liposomal sustained-release composition for use in treatment of pulmonary disease. The liposomal sustained release composition comprises a liposome that includes a polyethylene glycol (PEG)-modified lipid and encapsulates a tyrosine kinase inhibitor. Tyrosine kinase inhibitor is stably entrapped in the liposome, and the resulting liposomal drug formulation can be aerosolized or nebulized for administration via inhalation. This aerosolized liposomal drug formulation yields consistent pharmacokinetic and pharmacodynamic profiles while achieving desired efficacy and safety.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 27, 2022
    Assignee: INSPIRMED CORP.
    Inventors: Keelung Hong, Jonathan Fang, Yu-Cheng Tseng, Ting-Yu Cheng, Wan-Ni Yu, Jo-Hsin Tang
  • Patent number: 11529312
    Abstract: Embodiments of the present disclosure include anti-inflammatory compositions and methods of use thereof. The compositions include purified lipids from Francisella, for example, virulent strains of Francisella. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: December 20, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Catharine Mans Bosio, Robin M. Ireland, Glenn A. Nardone
  • Patent number: 11524080
    Abstract: The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: December 13, 2022
    Assignees: The Secretary of State for Defence, The University of Strathclyde
    Inventors: Ethel Diane Williamson, Riccardo Vincenzo D'Elia, Craig William Roberts, Stuart Woods
  • Patent number: 11505584
    Abstract: Embodiments of the disclosure provide a method for treatment of damaged lung tissue, e.g., lungs of a patient with a viral infection (e.g., coronavirus) and/or a bacterial infection and/or a parasitic pathogen or a patient whose lung tissue was damaged by exposure to a chemical, and a patient with acute respiratory distress syndrome (ARDS). Also provided is a method for protecting the brain from neuro-invasion and preventing inflammatory damage to organs remote from the lungs, by blocking cytokine synthesis in the lungs. The treatment includes administering a leptin antagonist (LepA) locally to the upper airways and/or to the lungs of the patient. Typically, the LepA is administered in an inhalable composition, such as, an aerosol.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: November 22, 2022
    Inventors: Jacob Schneiderman, Florian Douam
  • Patent number: 11464717
    Abstract: The present invention relates to oral care compositions comprising at least one biosurfactant and fluoride.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: October 11, 2022
    Assignee: Evonik Operations GmbH
    Inventors: Hans Henning Wenk, Kathrin Daniela Brandt, Martin Schilling, Verena Dahl, Jochen Kleinen, Joachim Venzmer
  • Patent number: 11458199
    Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: October 4, 2022
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Arturo Santos, Phillip Frost, Jane Hsiao
  • Patent number: 11452691
    Abstract: Embodiments of the present application relate to compositions of multivesicular liposomes (MVLs) and manufacturing processes for making bupivacaine MVLs.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: September 27, 2022
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Kathleen D. A. Los
  • Patent number: 11446247
    Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: September 20, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Noriyuki Kasagi, Naoki Yamada, Mikinaga Mori, Takayuki Kato, Takayuki Kobayashi